These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 19287287)

  • 1. Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections.
    Ladas ID; Karagiannis DA; Rouvas AA; Kotsolis AI; Liotsou A; Vergados I
    Retina; 2009 Mar; 29(3):313-8. PubMed ID: 19287287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term effectiveness of intravitreal bevacizumab versus ranibizumab injections for patients with neovascular age-related macular degeneration.
    Chang TS; Kokame G; Casey R; Prenner J; Feiner L; Anderson N
    Retina; 2009 Oct; 29(9):1235-41. PubMed ID: 19934818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal injection of 2.5 mg versus 1.25 mg bevacizumab (Avastin) for treatment of CNV associated with AMD.
    Modarres M; Naseripour M; Falavarjani KG; Nikeghbali A; Hashemi M; Parvaresh MM
    Retina; 2009 Mar; 29(3):319-24. PubMed ID: 19287288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effectivity and safety of bevacizumab intravitreal injections for exudative age-related macular degeneration treatment--6 months observations].
    Małgorzata F
    Klin Oczna; 2010; 112(7-9):213-6. PubMed ID: 21121123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Local and systemic complications after intravitreal administration of anti-vascular endothelial growth factor agents in the treatment of different ocular diseases: a five-year retrospective study.
    Nuzzi R; Tridico F
    Semin Ophthalmol; 2015 Mar; 30(2):129-35. PubMed ID: 24171832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration.
    Landa G; Amde W; Doshi V; Ali A; McGevna L; Gentile RC; Muldoon TO; Walsh JB; Rosen RB
    Ophthalmologica; 2009; 223(6):370-5. PubMed ID: 19590252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surveillance for potential adverse events associated with the use of intravitreal bevacizumab for retinal and choroidal vascular disease.
    Wong LJ; Desai RU; Jain A; Feliciano D; Moshfeghi DM; Sanislo SR; Blumenkranz MS
    Retina; 2008 Oct; 28(8):1151-8. PubMed ID: 18685542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
    Retina; 2007; 27(4):432-8. PubMed ID: 17420694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Large subretinal haemorrhage following change from intravitreal bevacizumab to ranibizumab.
    Karagiannis DA; Mitropoulos P; Ladas ID
    Ophthalmologica; 2009; 223(4):279-82. PubMed ID: 19390227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab.
    Fintak DR; Shah GK; Blinder KJ; Regillo CD; Pollack J; Heier JS; Hollands H; Sharma S
    Retina; 2008; 28(10):1395-9. PubMed ID: 18827737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety study of 38,503 intravitreal ranibizumab injections performed mainly by physicians in training and nurses in a hospital setting.
    Hasler PW; Bloch SB; Villumsen J; Fuchs J; Lund-Andersen H; Larsen M
    Acta Ophthalmol; 2015 Mar; 93(2):122-5. PubMed ID: 25403735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
    Rich RM; Rosenfeld PJ; Puliafito CA; Dubovy SR; Davis JL; Flynn HW; Gonzalez S; Feuer WJ; Lin RC; Lalwani GA; Nguyen JK; Kumar G
    Retina; 2006; 26(5):495-511. PubMed ID: 16770255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitrectomy after intravitreal bevacizumab (Avastin) for retinal detachment in retinopathy of prematurity.
    Kychenthal A; Dorta P
    Retina; 2010 Apr; 30(4 Suppl):S32-6. PubMed ID: 20224474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
    Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
    Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration.
    Stepien KE; Rosenfeld PJ; Puliafito CA; Feuer W; Shi W; Al-Attar L; Dubovy SR; Murray TG; Davis JL; Lee WH; Schwartz SG; Smiddy WE; Berrocal AM; Flynn HW
    Retina; 2009 Sep; 29(8):1067-73. PubMed ID: 19696701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results.
    Cleary CA; Jungkim S; Ravikumar K; Kelliher C; Acheson RW; Hickey-Dwyer M
    Eye (Lond); 2008 Jan; 22(1):82-6. PubMed ID: 17891059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicted biologic activity of intravitreal bevacizumab.
    Stewart MW
    Retina; 2007; 27(9):1196-200. PubMed ID: 18046224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bilateral simultaneous intravitreal injections in the office setting.
    Bakri SJ; Risco M; Edwards AO; Pulido JS
    Am J Ophthalmol; 2009 Jul; 148(1):66-9.e1. PubMed ID: 19403114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of hemorrhagic complications after intravitreal bevacizumab (avastin) or ranibizumab (lucentis) injections on systemically anticoagulated patients.
    Mason JO; Frederick PA; Neimkin MG; White MF; Feist RM; Thomley ML; Albert MA
    Retina; 2010 Oct; 30(9):1386-9. PubMed ID: 20924260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: results of the pan American collaborative retina study group at 24 months.
    Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ
    Retina; 2010; 30(7):1002-11. PubMed ID: 20616679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.